Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds

Yogita Rochlani, Naga Venkata Pothineni, Swathi Kovelamudi, Jawahar L. Mehta

Research output: Contribution to journalReview articlepeer-review

119 Scopus citations

Abstract

Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities that include hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia, and is strongly associated with an increased risk for developing diabetes and atherosclerotic and nonatherosclerotic cardiovascular disease (CVD). The pathogenesis of MetS involves both genetic and acquired factors that contribute to the final pathway of inflammation that leads to CVD. MetS has gained significant importance recently due to the exponential increase in obesity worldwide. Early diagnosis is important in order to employ lifestyle and risk factor modification. Here, we review the epidemiology and pathogenesis of MetS, the role of inflammation in MetS, and summarize existing natural therapies for MetS.

Original languageEnglish (US)
Pages (from-to)215-225
Number of pages11
JournalTherapeutic Advances in Cardiovascular Disease
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

Keywords

  • atherogenic dyslipidemia
  • cardiovascular disease
  • hypertension
  • insulin resistance
  • metabolic syndrome
  • nutraceuticals
  • obesity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds'. Together they form a unique fingerprint.

Cite this